Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Director | May 01, 2026 | May 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date May 01, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.82 · Expires 2036-05-01 | Direct | 48,800 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 48,800 · Balance 48,800 F1: The options were granted pursuant to the Company's non-employee director compensation policy. F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted pursuant to the Company's non-employee director compensation policy.
F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 1, 2026 20:18 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,800 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001527204-26-000002 · form4-05012026_080536.xml · derivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2036-05-01 F1 · security: The options were granted pursuant to the Company's non-employee director compensation policy. F2 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| December 29, 2025 Filed Dec 29, 2025 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 527 | $3.80 | $2,002.60 |
DisclosureSEC source: 0001527204-25-000005 · form4-12292025_041201.xml · nonDerivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527 Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 20:18 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,800 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001104659-25-094495 · tm2527377-6_4seq1.xml · derivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2035-09-25 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 25, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:33 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104438 · tm2425266-2_4seq1.xml · derivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 21:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 26,100 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001104659-23-105387 · tm2327241-2_4seq1.xml · derivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock, par value $0.0001 · 26,100 shares Expires 2033-09-28 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 29, 2022 Filed Oct 1, 2022 01:22 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 23,500 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001104659-22-104781 · tm2227177-7_4seq1.xml · derivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock, par value $0.0001 · 23,500 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 29, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 17,610 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001104659-22-075223 · tm2219797-1_4seq1.xml · derivative · entry 3 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,390 Underlying: Common Stock, par value $0.0001 · 40,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying the option become vested and exercisable in 36 substantially equal monthly installments, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 17,610 | $11.75 | $206,943.92 |
DisclosureSEC source: 0001104659-22-075223 · tm2219797-1_4seq1.xml · nonDerivative · entry 2 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.75 to $11.88, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 17,610 | $3.15 | $55,471.50 |
DisclosureSEC source: 0001104659-22-075223 · tm2219797-1_4seq1.xml · nonDerivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2021 Filed Oct 1, 2021 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 24,100 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001104659-21-122158 · tm2128463-4_4seq1.xml · derivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,100 Underlying: Common Stock, par value $0.0001 · 24,100 shares Expires 2031-09-23 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 23, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 22:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 9,500 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0000899243-20-026412 · doc4.xml · derivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock, par value $0.0001 · 9,500 shares Expires 2030-09-24 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 24, 2020, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| May 11, 2020 Filed May 12, 2020 20:49 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 40,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0000899243-20-012840 · doc4.xml · derivative · entry 1 Jorkasky Diane · CIK 0001527204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock, par value $0.0001 · 40,000 shares Expires 2030-05-11 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in 36 substantially equal monthly installments, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.